Collegium Pharmaceutical (NASDAQ:COLL) Reaches New 1-Year Low – What’s Next?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) reached a new 52-week low on Monday . The company traded as low as $26.64 and last traded at $27.50, with a volume of 205614 shares trading hands. The stock had previously closed at $28.14.

Wall Street Analyst Weigh In

COLL has been the subject of several recent research reports. Piper Sandler cut their price target on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research note on Tuesday, February 4th. Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a research report on Friday, January 10th. Finally, HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $43.60.

Collegium Pharmaceutical Price Performance

The firm has a market capitalization of $879.77 million, a P/E ratio of 11.80 and a beta of 0.76. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The business’s 50 day moving average is $29.88 and its 200-day moving average is $32.03.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The company had revenue of $181.95 million for the quarter, compared to analyst estimates of $179.68 million. As a group, sell-side analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 40,000 shares of the business’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the sale, the executive vice president now owns 154,204 shares of the company’s stock, valued at approximately $4,330,048.32. The trade was a 20.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Colleen Tupper sold 1,949 shares of the company’s stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $30.00, for a total transaction of $58,470.00. Following the transaction, the chief financial officer now owns 177,195 shares of the company’s stock, valued at $5,315,850. This trade represents a 1.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 109,193 shares of company stock valued at $3,243,594. 3.98% of the stock is currently owned by corporate insiders.

Institutional Trading of Collegium Pharmaceutical

A number of hedge funds have recently made changes to their positions in the company. New Age Alpha Advisors LLC acquired a new position in shares of Collegium Pharmaceutical in the fourth quarter valued at approximately $40,000. TD Private Client Wealth LLC boosted its position in Collegium Pharmaceutical by 39.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock worth $66,000 after buying an additional 483 shares during the period. KBC Group NV grew its holdings in Collegium Pharmaceutical by 72.5% during the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock worth $67,000 after acquiring an additional 982 shares during the last quarter. Virtus Fund Advisers LLC grew its holdings in Collegium Pharmaceutical by 30.5% during the 4th quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company’s stock worth $69,000 after acquiring an additional 565 shares during the last quarter. Finally, Nisa Investment Advisors LLC increased its position in Collegium Pharmaceutical by 14.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock valued at $71,000 after acquiring an additional 316 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.